Tectonic Therapeutic (TECX) AI Stock Analysis

• Market Cap: $348.06M
• Dividend Yield: N/A
• Average Volume (3M): 234.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: N/A
• EPS Growth: -343.40%
• Country: US
• Employees: 51
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -8.20
• Shares Outstanding: 18,662,672
• 10 Day Avg. Volume: 262,039
• 30 Day Avg. Volume: 234,978
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 5778.14
• Price to Cash Flow (P/CF): -4.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $82.00
• Price Target Upside: 339.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Tectonic Therapeutic is facing significant financial challenges with no revenue and ongoing losses, which are the most pressing concerns. However, the recent capital raise and promising trial results provide some optimism. The technical indicators suggest a bearish market outlook, while valuation metrics highlight the need for revenue generation. Overall, the stock is rated low due to its financial instability and uncertain path to profitability.

Positive Factors

Clinical Trial Results

TX45 delivered highly encouraging Ph1b Part A interim results, with full data to be presented at a medical meeting later this year.

Market Opportunity

TECX will report Ph1b data in PH-HFrEF, an indication that could potentially double TX45’s market opportunity.

Valuation

TECX is undervalued given noise around a competitor's discontinuation of their program in a different indication and some misconceptions around the relaxin mechanism.

Negative Factors

Potential Side Effects

A transient, asymptomatic 5-12 mmHg mean decrease in systemic blood pressure was observed post-IV dosing, which resolved at subsequent visits.

Stock Performance

TECX is -52% YTD due to LLY discontinuing their relaxin program and the bear point that TX45 is not an anti-fibrotic.

Tectonic Therapeutic Business Overview & Revenue Model

Company Description

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

How the Company Makes Money

Tectonic Therapeutic makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model includes income from product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. Key revenue streams involve upfront payments, milestone payments, and royalties from licensing its technology or drug candidates to larger pharmaceutical firms. Additionally, Tectonic may engage in collaborative research and development partnerships to further enhance its pipeline, leveraging external expertise while sharing costs and potential profits.

Tectonic Therapeutic Financial Statement Overview

Summary

Tectonic Therapeutic displays typical financial patterns for an R&D-focused biotech with high expenses and no revenue. A strong equity position limits immediate financial risk, but ongoing losses and negative cash flow necessitate future revenue or additional financing.

Income Statement

Tectonic Therapeutic has no revenue generation presently, which is typical for early-stage biotech firms. However, consistent increases in EBIT and net losses indicate high operational costs and potentially unsustainable financial health without future revenue streams. No revenue growth metrics are applicable.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of 89.1% TTM, indicating low leverage and significant equity financing. However, the Debt-to-Equity Ratio is low (1.98% TTM), reflecting minimal debt usage, which can be favorable in reducing financial risk but limits potential leverage benefits.

Cash Flow

Negative free cash flow indicates cash outflows exceed inflows, which is concerning without revenue. The operating cash flow to net income ratio is unavailable due to negative figures, indicating difficulties in converting income into cash. Cash reserves from financing activities provide temporary relief but are not sustainable long-term.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-264.00K	-617.00K	-4.17M	-1.40M	-1.21M	-850.00K
	EBIT
-48.30M	-44.65M	-105.43M	-118.84M	-120.23M	-75.81M
	EBITDA
-45.46M	-43.17M	-101.42M	-117.50M	-118.50M	-72.11M
	Net Income Common Stockholders
-45.98M	-42.82M	-105.89M	-119.13M	-119.71M	-72.97M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
98.30M	28.77M	92.85M	189.57M	259.68M	187.04M
	Total Assets
101.09M	101.09M	103.95M	203.84M	271.23M	200.51M
	Total Debt
878.00K	4.34M	16.46M	14.95M	0.00	0.00
	Net Debt
-97.42M	-24.43M	-76.38M	-174.62M	-259.68M	-187.04M
	Total Liabilities
6.35M	6.35M	28.58M	34.36M	16.89M	14.50M
	Stockholders Equity
94.74M	94.74M	75.37M	169.48M	254.34M	186.01M
Cash Flow		Free Cash Flow
-35.37M	-40.96M	-97.47M	-100.49M	-99.98M	-69.25M
	Operating Cash Flow
-35.22M	-40.68M	-97.21M	-98.03M	-98.80M	-67.67M
	Investing Cash Flow
-3.00K	-279.00K	-267.00K	-2.46M	-1.18M	-1.58M
	Financing Cash Flow
-6.02M	33.75M	262.00K	30.37M	172.62M	129.99M

Tectonic Therapeutic Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECX, the sentiment is Negative. The current price of 18.65 is below the 20-day moving average (MA) of 22.22, below the 50-day MA of 30.95, and below the 200-day MA of 30.17, indicating a bearish trend. The MACD of -3.10 indicates Negative momentum. The RSI at 31.98 is Neutral, neither overbought nor oversold. The STOCH value of 3.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECX.

Tectonic Therapeutic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BEAM	50 Neutral	$2.22B	―	-43.94%	―	-83.18%	-144.95%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
CRSP	46 Neutral	$3.17B	―	-19.20%	―	-89.95%	-123.71%
SGMO	41 Neutral	$184.26M	―	-187.83%	―	-67.20%	64.66%
EDIT	39 Underperform	$103.72M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$835.39M	―	-54.00%	―	59.55%	3.09%
TECX	34 Underperform	$348.06M	―	-42.09%	―	―	-343.40%

Tectonic Therapeutic Corporate Events

Tectonic Therapeutic Secures $185 Million in PIPE Deal

On February 3, 2025, Tectonic Therapeutic, Inc. announced a $185 million private placement agreement with accredited investors to fund its development pipeline, working capital, and general corporate purposes. The private investment in public equity (PIPE) involves the sale of 3,689,465 shares of common stock, with the transaction expected to close on February 5, 2025. The financing will support the clinical development of TX45 and TX2100, as well as the company’s discovery platform. The shares are sold under Regulation D’s exemption and are not registered under the Securities Act of 1933. This move is expected to enhance Tectonic’s operational capacity and industry positioning by providing necessary capital for its ongoing and future projects.

Tectonic Therapeutic Reports Positive Interim Results for TX45

On January 30, 2025, Tectonic Therapeutic announced positive interim results from its Phase 1b trial of TX45 in patients with Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results, which achieved all hemodynamic goals, bolster the potential for TX45’s continued development into Phase 2 trials, potentially addressing unmet needs in a market with significant revenue potential.

Tectonic Therapeutic Highlights Pipeline and Financial Strength

Tectonic Therapeutic has updated its corporate presentation, highlighting its pipeline and financial status. The company is advancing its lead product, TX45, targeting Group 2 Pulmonary Hypertension with ongoing Phase 1b and upcoming Phase 2 trials, aiming to address a significant unmet need with no current approved therapies. The company’s financial position is robust, with sufficient funds to support operations until mid-2027, and it is preparing to initiate a Phase 1 trial for another product, TX2100, targeting Hereditary Hemorrhagic Telangiectasia.